7,8-DidehydrocimigenolCAS# 150972-72-8 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 150972-72-8 | SDF | Download SDF |
| PubChem ID | 101577840 | Appearance | Cryst. |
| Formula | C30H46O5 | M.Wt | 486.7 |
| Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| SMILES | CC1CC2C(OC3(C1C4(CCC56CC57CCC(C(C7CC=C6C4(C3O)C)(C)C)O)C)O2)C(C)(C)O | ||
| Standard InChIKey | VFWGQUZLHBLDFF-OSIIPQMASA-N | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. 7,8-Didehydrocimigenol upregulates PPAR-γ in EC inhibits NF-kB activity of TNF-α-activated EC which leads to selective inhibition of VCAM-1 expression. 2. 7,8-Didehydrocimigenol can be used for the treatment of cardiovascular disorders such as atherosclerosis. |
| Targets | TNF-α | PPAR | NF-kB | ERK | Akt | IkB | IKK |
7,8-Didehydrocimigenol Dilution Calculator
7,8-Didehydrocimigenol Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.0547 mL | 10.2733 mL | 20.5465 mL | 41.0931 mL | 51.3663 mL |
| 5 mM | 0.4109 mL | 2.0547 mL | 4.1093 mL | 8.2186 mL | 10.2733 mL |
| 10 mM | 0.2055 mL | 1.0273 mL | 2.0547 mL | 4.1093 mL | 5.1366 mL |
| 50 mM | 0.0411 mL | 0.2055 mL | 0.4109 mL | 0.8219 mL | 1.0273 mL |
| 100 mM | 0.0205 mL | 0.1027 mL | 0.2055 mL | 0.4109 mL | 0.5137 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 2,4,4'-Trihydroxydihydrochalcone
Catalog No.:BCN7365
CAS No.:15097-74-2
- Tirofiban hydrochloride monohydrate
Catalog No.:BCC2003
CAS No.:150915-40-5
- D-allo-Ile-OH
Catalog No.:BCC2966
CAS No.:1509-35-9
- Aurantiamide benzoate
Catalog No.:BCN8043
CAS No.:150881-02-0
- Euonymine
Catalog No.:BCN3084
CAS No.:150881-01-9
- Bis(phenylacetyl) disulfide
Catalog No.:BCC8887
CAS No.:15088-78-5
- Uralenol-3-methylether
Catalog No.:BCN7993
CAS No.:150853-98-8
- Micromelin
Catalog No.:BCN1672
CAS No.:15085-71-9
- Boc-Orn(Fmoc)-OH
Catalog No.:BCC3429
CAS No.:150828-96-9
- EGF816
Catalog No.:BCC6428
CAS No.:1508250-71-2
- Nitenpyram
Catalog No.:BCC5559
CAS No.:150824-47-8
- 2,3,24-Trihydroxyolean-12-en-28-oic acid
Catalog No.:BCN1559
CAS No.:150821-16-2
- Boc-Lys(Boc)-OH.DCHA
Catalog No.:BCC3413
CAS No.:15098-69-8
- H-Phe-OtBu.HCl
Catalog No.:BCC3011
CAS No.:15100-75-1
- DOXO-EMCH
Catalog No.:BCC1537
CAS No.:151038-96-9
- L-701,252
Catalog No.:BCC6755
CAS No.:151057-13-5
- Moxifloxacin
Catalog No.:BCC4227
CAS No.:151096-09-2
- Haloperidol hydrochloride
Catalog No.:BCC4251
CAS No.:1511-16-6
- 4-Difluoromethoxy-3-hydroxybenzaldehyde
Catalog No.:BCC8706
CAS No.:151103-08-1
- 8-(6-Hydroperoxy-3,7-dimethyl-2,7-octadienyloxy)psoralen
Catalog No.:BCN1558
CAS No.:151121-39-0
- CL 316243 disodium salt
Catalog No.:BCC7091
CAS No.:151126-84-0
- 4'-Hydroxy-2,4-dimethoxychalcone
Catalog No.:BCC8708
CAS No.:151135-64-7
- Borapetoside D
Catalog No.:BCN6612
CAS No.:151200-48-5
- Borapetoside E
Catalog No.:BCN6571
CAS No.:151200-49-6
7,8-didehydrocimigenol from Cimicifugae rhizoma inhibits TNF-alpha-induced VCAM-1 but not ICAM-1expression through upregulation of PPAR-gamma in human endothelial cells.[Pubmed:20946932]
Food Chem Toxicol. 2011 Jan;49(1):166-72.
Activators of PPAR have been demonstrated to inhibit the induction of VCAM-1 but not ICAM-1 in human endothelial cells (EC). During the screening of anti-inflammatory activity of traditional herbs, we found 7,8-Didehydrocimigenol (7,8-DHC), one of active triterpenoids of Cimicifugae rhizoma (C. rhizoma) increases PPAR-gamma expression in EC in a time- and dose-dependent manner. Therefore, we asked whether 7,8-DHC selectively inhibits the expression of VCAM-1 but not ICAM-1 in TNF-alpha-activated EC via upregulation of PPAR-gamma. Treatment with 7,8-DHC or PPAR-gamma agonists (GW1929, troglitazone) inhibited the expression of VCAM-1 but not ICAM-1. Furthermore, the selective inhibition of VCAM-1 expression was inhibited by PPAR-gamma antagonist, GW9662, or siPPAR-gamma-transfected cells. 7,8-DHC significantly inhibited NF-kB activity via inhibition of phosphorylation of IkB and it also inhibited phosphorylation of ERK1/2 and Akt but not PKC. Finally, attachment of monocytes (U937) to EC by TNF-alpha was significantly reduced by 7,8-DHC. These results indicate that upregualtion of PPAR-gamma by 7,8-DHC in EC inhibits NF-kB activity of TNF-alpha-activated EC which leads to selective inhibition of VCAM-1 expression. In addition, ERK1/2 and Akt signal pathways are involved in differential regulation by 7,8-DHC. We concluded that 7,8-DHC can be used for the treatment of cardiovascular disorders such as atherosclerosis.
